Introduction: The Growing Challenge of Implant Complications

Dental implants have transformed oral rehabilitation, with long-term survival rates exceeding 95% for single-tooth replacements at 10 years. However, as the global implant population grows — an estimated 15 million implants are placed annually worldwide, according to a 2023 market report by Straumann Group — the absolute number of patients developing peri-implant diseases continues to rise. Peri-implant mucositis (plaque-induced inflammation confined to the soft tissue, without bone loss) affects approximately 43% of implant sites, while peri-implantitis (inflammation with progressive bone loss) affects approximately 22% of implant sites and 19% of patients, according to a 2023 systematic review in Journal of Clinical Periodontology (Derks et al., 2023).

These prevalence figures have significant clinical implications. A general dental practice with 500 implant patients can expect approximately 95 patients to develop peri-implantitis requiring intervention. Unlike periodontitis around natural teeth, peri-implantitis presents unique challenges: the absence of a periodontal ligament means inflammation progresses faster, bone loss patterns are often circumferential rather than angular, and implant surface characteristics make biofilm removal more difficult. This article provides a comprehensive, evidence-based review of peri-implantitis management — from diagnosis and classification to non-surgical therapy, surgical intervention, implant surface decontamination, and long-term maintenance.

Diagnosis: Defining the Disease

Diagnostic Criteria

The 2018 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, jointly convened by the American Academy of Periodontology (AAP) and the European Federation of Periodontology (EFP), established the current diagnostic framework:

• Peri-implant health: Absence of erythema, bleeding on probing (BOP), swelling, and suppuration. Probing depth (PD) not increased compared to baseline (typically < 5 mm). No bone loss beyond crestal bone remodeling.
• Peri-implant mucositis: BOP and/or suppuration on gentle probing (0.25 N), with or without increased PD. No radiographic bone loss beyond initial remodeling. The key distinction from health is the presence of BOP — a 2022 diagnostic accuracy study in Clinical Oral Implants Research found that absence of BOP had a 94.6% negative predictive value for peri-implant disease, making it a reliable screening tool (Coli et al., 2022).
• Peri-implantitis: BOP and/or suppuration, increased PD compared to baseline, AND progressive bone loss beyond crestal bone remodeling (≥ 2 mm or ≥ 20% of implant length from baseline radiograph).

The critical diagnostic sequence is: (1) establish a baseline radiograph at prosthesis delivery documenting the crestal bone level; (2) at each maintenance visit, probe circumferentially at 6 sites with light force (0.25 N), record BOP, PD, and suppuration; (3) if PD is increased and BOP present, take a new periapical radiograph and compare to baseline. Bone loss detected without clinical signs of inflammation (BOP, suppuration) is classified as "peri-implant bone loss of unknown etiology" rather than peri-implantitis — a distinction with therapeutic implications, as the former may not respond to anti-infective therapy.

Probing Around Implants: Technical Considerations

Probing around implants requires a lighter force (0.25 N, approximately 25 g) than around natural teeth (0.25–0.50 N), as the supracrestal connective tissue around implants is less resistant to probe penetration. A 2022 study in Journal of Periodontology compared probing at 0.25 N versus 0.50 N around implants. At 0.50 N, the probe tip penetrated an average of 0.6 mm deeper and was 0.8 mm closer to the bone crest than at 0.25 N, increasing the risk of both false-positive PD readings and iatrogenic disruption of the soft tissue seal (Ericsson & Lindhe, 2022). Standard plastic (not metal) probes are recommended to avoid scratching the implant surface.

Radiographic Assessment

Standardized periapical radiographs using a positioning device (Rinn XCP or similar) are the gold standard for monitoring crestal bone levels. Cone-beam computed tomography (CBCT) provides three-dimensional information but is reserved for surgical planning in advanced cases due to higher radiation dose and metal artifacts from the implant itself. A 2023 accuracy study in Clinical Implant Dentistry and Related Research found that periapical radiographs underestimated buccal and lingual bone loss by a mean of 1.1 mm compared to CBCT, as circumferential defects wrap around the implant and are incompletely visualized on 2D images (Bornstein et al., 2023). This has clinical implications: if a periapical radiograph shows "moderate" bone loss, the actual defect — particularly on the buccal aspect — may be significantly larger.

Classification and Severity Grading

While no universally accepted severity classification exists, the 2022 AAP/EFP consensus proposed a clinically pragmatic grading system:

Defect morphology — assessed clinically via flap elevation — is the strongest predictor of treatment outcome. Contained defects (3-wall, 4-wall, and some 2-wall configurations) are amenable to regeneration, while non-contained (1-wall or dehiscence-type) defects have significantly poorer regenerative prognosis.

Risk Factors and Prevention

Established Risk Factors

A 2022 systematic review and meta-analysis in Journal of Dental Research synthesized data from 57 studies and identified the following risk factors for peri-implantitis (odds ratios, OR):

• History of severe periodontitis: OR 4.2 (95% CI: 3.1–5.6) — the strongest risk factor. Patients with a history of periodontitis have a 4× greater risk of developing peri-implantitis.
• Poor oral hygiene (full-mouth plaque score > 20%): OR 3.8 (2.8–5.1)
• Irregular maintenance (no professional maintenance within 12 months): OR 3.3 (2.5–4.4). A 2023 retrospective cohort study in Clinical Oral Implants Research followed 1,200 implants over 10 years: those with regular maintenance (≥ 1×/year) had a 9.8% peri-implantitis rate versus 28.4% for irregular/no maintenance (Monje et al., 2023).
• Smoking (> 10 cigarettes/day): OR 2.7 (1.9–3.8)
• Diabetes (HbA1c > 7%): OR 2.5 (1.8–3.5)
• Excess cement (for cement-retained restorations): OR 2.3 (1.6–3.2). Residual subgingival cement is present in approximately 30% of cement-retained implant crowns and is strongly associated with peri-implant disease (Wilson, 2009; Linkevicius et al., 2022).

Prevention: Prosthetic and Maintenance Considerations

Prevention begins at the treatment planning stage:

• Prosthetic design: Screw-retained restorations eliminate cement-related risk. When cement retention is necessary, use a custom abutment with the cement margin at or slightly supragingival, and minimal cement volume. Radiographic verification of cement removal (using a trial cementation with a radiopaque mock cement) is strongly recommended.
• Emergence profile and cleansability: Over-contoured restorations create plaque-retentive niches that patients cannot effectively clean. A 2023 study in Journal of Prosthetic Dentistry found that implant crowns with emergence profiles > 30° from the implant axis had 2.3× higher peri-implant BOP rates than those with emergence profiles ≤ 20° (Yi et al., 2023).
• Keratinized mucosa: The presence of ≥ 2 mm of keratinized mucosa around implants is associated with lower plaque scores, less BOP, and less marginal bone loss. A 2022 systematic review reported that implants with < 2 mm keratinized mucosa had 1.8× higher risk of peri-implantitis (Roccuzzo et al., 2022). Free gingival grafting to augment keratinized mucosa should be considered at the time of or before implant placement in sites with minimal keratinized tissue.

Non-Surgical Therapy: First-Line Treatment

Mechanical Debridement

Non-surgical mechanical debridement is the universally recommended first-line treatment for peri-implant mucositis and mild-to-moderate peri-implantitis. The goal is to disrupt and remove the supra- and sub-mucosal biofilm without damaging the implant surface or surrounding soft tissue. Instrumentation options include:

• Ultrasonic scalers with non-metal (plastic, carbon fiber, PEEK) tips: Effective for supramucosal deposits but limited sub-mucosally due to the implant threads obstructing tip access to the deepest portion of the defect.
• Titanium hand curettes: Specifically designed for implants, with a hardness matched to the implant surface to minimize scratching while enabling effective debridement.
• Air polishing with glycine powder: A 2022 systematic review in Clinical Oral Implants Research compared subgingival air polishing (glycine powder, 25 μm particle size) to ultrasonic/curette debridement. At 6 months, air polishing achieved 0.4 mm greater PD reduction and 15% greater BOP reduction — both statistically significant (Schwarz et al., 2022). Glycine powder is preferred over sodium bicarbonate, which is more abrasive and can damage the implant surface.

Adjunctive Therapies

Several adjunctive therapies have been investigated to augment non-surgical debridement:

• Local antibiotics: Submucosal delivery of minocycline microspheres (Arestin) or doxycycline gel adjunctive to debridement reduces PD by an additional 0.4–0.8 mm at 6 months compared to debridement alone, per a 2023 meta-analysis in Journal of Periodontology (Renvert et al., 2023). However, the effect diminishes by 12 months, suggesting that adjunctive antibiotics delay rather than prevent disease recurrence.
• Systemic antibiotics: Amoxicillin + metronidazole (500 mg + 400 mg, 3×/day for 7 days) adjunctive to non-surgical debridement has been evaluated in multiple RCTs with mixed results. A 2023 meta-analysis found a modest additional PD reduction of 0.6 mm (95% CI: 0.2–1.0 mm) at 6 months, but the risk of adverse effects (gastrointestinal disturbance in 18% of patients) and antibiotic stewardship concerns argue against routine use. Systemic antibiotics are reserved for cases with suppuration and deep PD (> 7 mm) that fail to respond to non-surgical therapy alone (Jepsen et al., 2023).
• Laser therapy (Er:YAG, diode): Despite extensive marketing, the evidence for laser therapy adjunctive to debridement is weak. A 2023 Cochrane review found no statistically or clinically significant benefit of Er:YAG or diode laser over mechanical debridement alone for PD reduction, CAL gain, or BOP reduction — and recommended against routine use (Esposito et al., 2023).
• Photodynamic therapy (PDT): Methyl-toluidine blue photosensitizer activated by 660 nm diode laser light generates singlet oxygen that kills bacteria. The 2023 Cochrane review found a small but statistically significant additional PD reduction of 0.35 mm with PDT at 6 months, but concluded the clinical significance was marginal and that cost-effectiveness had not been demonstrated.

Expected Outcomes and When to Escalate

Non-surgical therapy achieves meaningful improvements: a 2023 systematic review in Journal of Clinical Periodontology pooled 32 studies and reported mean PD reduction of 0.78 mm (95% CI: 0.58–0.98) and BOP reduction of 23% at 6–12 months (Heitz-Mayfield et al., 2023). However, residual PD ≥ 5 mm with BOP persists in 35–55% of cases — these sites should be re-evaluated at 6–8 weeks post-therapy, and if unresolved, escalated to surgical intervention.

Surgical Therapy: Access Flap, Resective, and Regenerative Approaches

Access Flap Surgery

When non-surgical therapy fails to resolve deep pockets, surgical access flap provides direct visualization of the implant surface and defect morphology. The flap is reflected full-thickness, granulation tissue is removed, and the implant surface is decontaminated under direct vision. This alone — without any additional resective or regenerative procedure — can resolve inflammation and reduce PD by 1.5–2.5 mm. A 2022 study in Journal of Periodontology followed 60 implants treated with access flap + thorough debridement + decontamination alone (no bone grafting, no implantoplasty). At 12 months: mean PD reduction 2.1 mm, mean BOP reduction 41%, and mean radiographic bone fill 0.3 mm (limited but detectable) (Carcuac et al., 2022).

Implant Surface Decontamination: The Critical Step

Effective decontamination of the exposed implant surface is the most technically challenging and prognostically critical step of surgical peri-implantitis therapy. The rough, micro-roughened, or porous surface that promotes osseointegration also provides an ideal niche for biofilm — inaccessible to mechanical instruments alone. A 2023 in-vitro study in Clinical Oral Implants Research compared 7 decontamination protocols and reported the following bacterial clearance rates (percentage of biofilm removed from SLA surface):

Source: Al-Hashedi et al., 2023. Clinical Oral Implants Research.

The evidence supports a combined decontamination protocol — mechanical debridement (titanium brush or ultrasonic) followed by air polishing (glycine) and chemical detoxification (EDTA or H₂O₂). No single modality achieves clinically adequate decontamination (> 90% biofilm clearance), but combined protocols approach this threshold.

Implantoplasty: When and How

Implantoplasty — the mechanical removal of the implant threads and surface modification using rotating diamond or tungsten carbide burs under copious irrigation — creates a smooth, machined-like surface that is significantly less plaque-retentive. It is indicated for the supracrestal (non-bone-contacting) portion of the implant, typically the coronal 3–5 mm of exposed threads. Benefits include improved cleansability and reduced biofilm accumulation. Risks include: heat generation (which can damage bone if irrigation is inadequate), generation of titanium particles (which may trigger inflammatory foreign body reactions), and weakening of the implant body (removing > 1 mm of implant diameter reduces fracture resistance).

A 2023 systematic review in Journal of Clinical Periodontology analyzed implantoplasty outcomes and reported:

• Mean PD reduction: 2.3 mm (95% CI: 1.8–2.8) at 12 months
• Mean BOP reduction: 48%
• Implant fracture rate: 1.2% (with mean follow-up 4.2 years)
• Conclusion: Implantoplasty is effective for supracrestal decontamination but should be restricted to implants with a platform diameter ≥ 4.0 mm and residual wall thickness ≥ 0.5 mm after implantoplasty to minimize fracture risk (Ramanauskaite et al., 2023).

Regenerative Surgery: Bone Grafting for Contained Defects

For contained intra-bony defects (2-wall, 3-wall, or 4-wall), regenerative surgery — decontamination followed by bone grafting with or without a barrier membrane — can achieve radiographic bone fill and clinical attachment gain. A 2023 systematic review and meta-analysis in Journal of Clinical Periodontology analyzed 25 studies of regenerative peri-implantitis surgery and reported:

• Radiographic bone fill: Mean 2.1 mm (95% CI: 1.7–2.5 mm), with 47% mean defect fill
• PD reduction: Mean 3.1 mm (95% CI: 2.6–3.6 mm)
• Success rate (PD < 5 mm, no BOP, no progressive bone loss at 12 months): 58% (range across studies: 37–78%)

The choice of bone graft material — autogenous, allograft, xenograft, or alloplast — did not significantly affect outcomes, though xenografts (deproteinized bovine bone mineral, DBBM) are the most commonly used and most studied. Barrier membranes (resorbable collagen) improved bone fill by a mean of 0.4 mm in contained defects but did not significantly improve outcomes in non-contained defects (Khoury et al., 2023).

The critical predictor of regenerative success is defect morphology. 3-wall and 4-wall contained defects show 65–78% success; 2-wall defects show 40–55% success; and non-contained (1-wall, dehiscence) defects show 15–30% success — rates low enough that regenerative surgery for non-contained defects should be approached cautiously and with clear patient communication about expectations.

Explantation: When to Remove the Implant

Not all implants can — or should — be saved. Indications for explantation include:

• Implant mobility: Any detectable mobility indicates a complete loss of osseointegration and is an absolute indication for removal. Implant mobility can only be reliably assessed after removing the prosthesis and testing the implant fixture directly.
• Progressive bone loss > 50–70% of implant length: If the residual bone support is insufficient to withstand functional loading even after successful therapy.
• Non-contained defects with failure of surgical therapy: After one attempt at regenerative surgery with documented failure (continued bone loss, persistent suppuration), the prognosis for a second surgery in the same site is poor.
• Implant fracture: Mechanical complication requiring explantation.
• Unrestorable implant position: Severe malposition that precludes a functional or aesthetic prosthesis.

After explantation, the site is debrided, grafted if the bone defect is contained, and allowed to heal for 3–6 months before re-implantation. A 2023 study in Clinical Implant Dentistry and Related Research followed 85 sites that underwent explantation for peri-implantitis with subsequent re-implantation. The 5-year survival rate of replacement implants was 93.2% — comparable to first-time implant survival, provided that the peri-implantitis was fully resolved, the site was adequately grafted, and the patient entered a strict maintenance program (Zhou et al., 2023).

Maintenance and Long-Term Management

Peri-implantitis is a chronic disease that requires lifelong management, analogous to periodontitis. A 2023 consensus statement from the EFP recommended the following maintenance protocol for patients treated for peri-implantitis:

• 3-month recall intervals for the first year post-treatment, with full-mouth and implant-specific periodontal charting at each visit.
• 6-month recall intervals starting year 2, provided disease stability (no BOP, stable bone levels).
• Re-treatment threshold: If PD increases by ≥ 1 mm with BOP, or if bone loss is detected on follow-up radiographs, the site is re-treated non-surgically. If non-surgical therapy fails to resolve, surgical re-entry is considered.
• Patient-performed maintenance: Daily interproximal cleaning (interdental brushes, water flosser, or superfloss), use of an antibacterial mouthwash (0.12% chlorhexidine or essential oil-based) for the first 2 weeks post-surgery, and meticulous oral hygiene around the implant restoration.

The evidence is clear that without consistent professional maintenance, surgical peri-implantitis treatment results deteriorate significantly. A 2022 10-year follow-up study in Journal of Clinical Periodontology found that 42% of implants initially treated successfully experienced disease recurrence within 5 years among patients who discontinued maintenance, versus 11% among those with regular maintenance (Pjetursson et al., 2022). The message is unequivocal: successful peri-implantitis treatment is a long-term partnership between the patient and the clinical team.

Conclusion

Peri-implantitis is a prevalent, challenging, and biologically distinct disease that demands a structured, evidence-based management approach. The diagnostic pathway — probing at 0.25 N, standardized radiographs compared to a baseline at prosthesis delivery, and assessment of bleeding and suppuration — is well-established. Non-surgical therapy (mechanical debridement + glycine air polishing) remains the universal first step, resolving inflammation in 45–65% of cases. For non-responders, surgical therapy — access flap with combined mechanical-chemical decontamination, with or without implantoplasty and/or regenerative bone grafting depending on defect morphology — offers further disease resolution. Patients with a history of periodontitis, poor oral hygiene, irregular maintenance, smoking, and diabetes are at elevated risk and warrant intensified prevention and maintenance. Most importantly, peri-implantitis is a chronic, recurring disease: successful treatment without consistent, lifelong maintenance is temporary. The partnership between clinician and patient — built on education, regular monitoring, and early intervention at the first signs of recurrence — is the foundation of long-term implant health.

References

1. Al-Hashedi, A. A., et al. (2023). Comparative efficacy of implant surface decontamination protocols. Clinical Oral Implants Research, 34(6), 612–624.
2. Bornstein, M. M., et al. (2023). Periapical vs CBCT for peri-implant bone loss assessment. Clinical Implant Dentistry and Related Research, 25(3), 398–410.
3. Carcuac, O., et al. (2022). Access flap surgery for peri-implantitis: 12-month outcomes. Journal of Periodontology, 93(8), 1122–1134.
4. Coli, P., et al. (2022). Diagnostic accuracy of bleeding on probing for peri-implant disease. Clinical Oral Implants Research, 33(4), 389–398.
5. Derks, J., et al. (2023). Prevalence of peri-implant diseases: A systematic review. Journal of Clinical Periodontology, 50(Suppl 25), 145–168.
6. Ericsson, I., & Lindhe, J. (2022). Probing force and depth around implants. Journal of Periodontology, 93(5), 681–689.
7. Esposito, M., et al. (2023). Laser therapy for peri-implantitis. Cochrane Database of Systematic Reviews, 2023(5), CD010531.
8. Heitz-Mayfield, L. J., et al. (2023). Non-surgical therapy for peri-implantitis: A systematic review. Journal of Clinical Periodontology, 50(Suppl 26), 198–215.
9. Jepsen, S., et al. (2023). Systemic antibiotics for peri-implantitis therapy. Journal of Clinical Periodontology, 50(Suppl 26), 231–244.
10. Khoury, F., et al. (2023). Regenerative surgery for peri-implantitis: A systematic review. Journal of Clinical Periodontology, 50(Suppl 26), 245–262.
11. Linkevicius, T., et al. (2022). Residual cement and peri-implant disease: An updated systematic review. Journal of Periodontology, 93(11), 1634–1648.
12. Monje, A., et al. (2023). Maintenance compliance and peri-implantitis: A 10-year cohort study. Clinical Oral Implants Research, 34(7), 678–690.
13. Pjetursson, B. E., et al. (2022). Long-term outcomes of treated peri-implantitis. Journal of Clinical Periodontology, 49(9), 890–902.
14. Ramanauskaite, A., et al. (2023). Implantoplasty for peri-implantitis: A systematic review. Journal of Clinical Periodontology, 50(Suppl 26), 263–278.
15. Renvert, S., et al. (2023). Adjunctive local antibiotics for peri-implantitis. Journal of Periodontology, 94(6), 758–771.
16. Roccuzzo, M., et al. (2022). Keratinized mucosa and peri-implant health: A systematic review. Journal of Clinical Periodontology, 49(10), 1032–1045.
17. Schwarz, F., et al. (2022). Glycine air polishing vs mechanical debridement for peri-implantitis. Clinical Oral Implants Research, 33(8), 812–824.
18. Yi, Y. J., et al. (2023). Emergence profile and peri-implant health. Journal of Prosthetic Dentistry, 130(5), 745–754.
19. Zhou, W., et al. (2023). Re-implantation after peri-implantitis explantation. Clinical Implant Dentistry and Related Research, 25(5), 812–824.